Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has James Larkin's publication output changed over time?
ScholarIQpublication output · 2011–2019
Output grew0% over the shown period — from 1 works in 2011 to 1 in 2019.
1
4
3
1
2011201520172019
What are the most-cited papers on James Larkin?
ScholarIQmost cited works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B.A.G. Haanen, Michele Maio, Iván Márquez‐Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth F. Grossmann, Mario Sznol, Brigitte Dréno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine E. Horak, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20158,191 CitationsOPEN ACCESS
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Célèste Lebbé, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven O’Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dréno, K. B. Nolop, Jiang Li, B. Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
New England Journal of Medicine. 20117,715 CitationsOPEN ACCESS
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma
New England Journal of Medicine. 20155,914 CitationsOPEN ACCESS
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas
New England Journal of Medicine. 20155,885 CitationsOPEN ACCESS
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, David Hogg, John B.A.G. Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Iván Márquez‐Rodas, Massimo Guidoboni, Grant A. McArthur, Célèste Lebbé, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey A. Sosman, Michael A. Postow, Margaret K. Callahan, Dana Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin
New England Journal of Medicine. 20175,410 CitationsOPEN ACCESS
Related on ScholarIQ
University of California, Los Angeles
University
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Paper
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paper
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Paper
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Paper
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Paper